Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to $2.5 million.

  • Silence Therapeutics' Share-based Compensation fell 37.67% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year decrease of 28.52%. This contributed to the annual value of $16.3 million for FY2024, which is 0.20% up from last year.
  • As of Q3 2025, Silence Therapeutics' Share-based Compensation stood at $2.5 million, which was up 21.58% from $2.1 million recorded in Q2 2025.
  • Silence Therapeutics' 5-year Share-based Compensation high stood at $5.7 million for Q1 2023, and its period low was $1.9 million during Q4 2023.
  • Over the past 3 years, Silence Therapeutics' median Share-based Compensation value was $4.0 million (recorded in 2024), while the average stood at $3.7 million.
  • As far as peak fluctuations go, Silence Therapeutics' Share-based Compensation skyrocketed by 113.12% in 2024, and later plummeted by 49.65% in 2025.
  • Over the past 5 years, Silence Therapeutics' Share-based Compensation (MRQ) stood at $2.5 million in 2021, then decreased by 18.52% to $2.0 million in 2022, then dropped by 7.68% to $1.9 million in 2023, then soared by 113.12% to $4.0 million in 2024, then crashed by 36.32% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.1 million for Q2 2025, and $3.5 million during Q1 2025.